The most common side effects for treatment with Pomalyst and low-dose dexamethasone included neutropenia (low count of neutrophils, a type of white blood
Return any unused Pomalyst to your doctor, or as directed
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma
The median progression-free survival was 12
Dexamethasone is a steroid
However, conventional therapy is not curative and MM will ultimately relapse
We analyzed the efficacy and safety of pomalidomide, cyclophosphamide, and dexamethasone (PomCiDex) in a real-world RRMM population
The choice of pomalidomide is especially interesting owing to the synergistic antiproliferative activity of pomalidomide and dexamethasone in lenalidomide-resistant MM cells
The Pomalyst-based combination also led to more “durable and deeper responses,” researchers noted, with about three times as many patients achieving a very good partial response or better (52
As 1 example, in the ICARIA study, 47 evaluating isatuximab, pomalidomide, and dexamethasone vs pomalidomide and dexamethasone, 43% of patients required dose reductions of pomalidomide and 33% of patients required dose reductions in
et al
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma Richardson PG, Oriol A, Beksac M, et al; OPTIMISMM trial investigators
Dosing information
Results from the phase 3 OPTIMISMM trial (NCT01734928) demonstrated that pomalidomide (P) in combination with bortezomib + dexamethasone (Vd) significantly